Muralidhar Beeram

6.8k total citations
89 papers, 3.0k citations indexed

About

Muralidhar Beeram is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Muralidhar Beeram has authored 89 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 34 papers in Molecular Biology. Recurrent topics in Muralidhar Beeram's work include HER2/EGFR in Cancer Research (26 papers), Cancer Treatment and Pharmacology (24 papers) and Advanced Breast Cancer Therapies (21 papers). Muralidhar Beeram is often cited by papers focused on HER2/EGFR in Cancer Research (26 papers), Cancer Treatment and Pharmacology (24 papers) and Advanced Breast Cancer Therapies (21 papers). Muralidhar Beeram collaborates with scholars based in United States, Canada and South Korea. Muralidhar Beeram's co-authors include Amita Patnaik, Eric K. Rowinsky, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Howard A. Burris, Shanu Modi, Sandhya Girish, Drew Rasco, Ian E. Krop and Scott N. Holden and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Muralidhar Beeram

87 papers receiving 2.9k citations

Peers

Countries citing papers authored by Muralidhar Beeram

Since Specialization

Citations

This map shows the geographic impact of Muralidhar Beeram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muralidhar Beeram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muralidhar Beeram more than expected).

Fields of papers citing papers by Muralidhar Beeram

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muralidhar Beeram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muralidhar Beeram. The network helps show where Muralidhar Beeram may publish in the future.

Co-authorship network of co-authors of Muralidhar Beeram

This figure shows the co-authorship network connecting the top 25 collaborators of Muralidhar Beeram. A scholar is included among the top collaborators of Muralidhar Beeram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muralidhar Beeram. Muralidhar Beeram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study 2025 ·Frontiers in Oncology ·Sara M. Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L. Puhalla, Alison Conlin, (unknown), Muralidhar Beeram, Sonya C. Chapman, Andrew Lithio, Lacey M. Litchfield, Matthew P. Goetz	0
2	Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292 2024 ·Cancer Research ·Erika Hamilton, Patrick Neven, Barbara Pistilli, Muralidhar Beeram, Virginia F. Borges, Mario Campone, José Luiz Guimarães, Theodoros Foukakis, Annette Raskov Kodahl, Peter Lau, Elgene Lim, Iwona Ługowska, (unknown), Christopher Gresty, Claire Miller, Roberto Sommavilla, Dhivya R. Sudhan, Hope S. Rugo	2
3	Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. 2024 ·Journal of Clinical Oncology ·Manali Bhave, Komal Jhaveri, Peter A. Kaufman, Philippe Aftimos, Janine Lombard, Kostandinos Sideras, Seock‐Ah Im, X. Cynthia, (unknown), Sung‐Bae Kim, Yujia Li, Eunice Yuen, Shawn T. Estrem, Bastien Nguyen, (unknown), (unknown), Muralidhar Beeram, Joohyuk Sohn	0
4	Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study 2022 ·Frontiers in Oncology ·Sara M. Tolaney, Muralidhar Beeram, J. Thaddeus Beck, Alison Conlin, Elizabeth Claire Dees, Shannon L. Puhalla, Brent N. Rexer, Howard A. Burris, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N. Moore, Allison M. Manuel, Andrew Lithio, Gregory L. Price, Sonya C. Chapman, Lacey M. Litchfield, Matthew P. Goetz	11
5	Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers. 2017 ·Journal of Clinical Oncology ·Diana F. Hausman, Erika Hamilton, Muralidhar Beeram, (unknown), Gordon Ng, Funda Meric‐Bernstam	11
6	Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer 2017 ·Cancer Chemotherapy and Pharmacology ·Jeffrey R. Infante, Amita Patnaik, Claire F. Verschraegen, Anthony J. Olszanski, Montaser Shaheen, Howard A. Burris, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Scott M. Hynes, Jennifer Leohr, Aimee Bence Lin, Lily Q. Li, Anna McGlothlin, Daphne L. Farrington, Eric H. Westin, Roger B. Cohen	29
7	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors 2015 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni R. Abdul Razak, Katherine Van Loon, Amita Patnaik, Philippe L. Bédard, (unknown), Muralidhar Beeram, Lieve Adriaens, Carrie Brownstein, Israel Lowy, Ana Kostić, Pamela A. Trail, Bo Gao, A. Thomas DiCioccio, Lillian L. Siu	59
8	Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Toshio Shimizu, Patricia LoRusso, K. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon Smith, Drew Rasco, Theresa A. Mays, (unknown), Anna Ma, Jing Wang, Robert J Laliberte, Maurizio Voi, Anthony W. Tolcher	67
9	Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma 2014 ·Cancer Chemotherapy and Pharmacology ·Devalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, Jordi Rodón, Kamalesh K. Sankhala, Alain C. Mita, Daniel K. Benjamin, Norma S. Ketchum, Joel Michalek, Anthony W. Tolcher, John J. Wright, John Sarantopoulos	24
10	A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors 2014 ·Investigational New Drugs ·Colin D. Weekes, Muralidhar Beeram, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Lia Gore, Priti S. Hegde, Xin Yan, Ron Yu, L-Y Shih, Hong Xiang, Rainer K. Brachmann, Amita Patnaik	72
11	A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Amita Patnaik, Patricia LoRusso, Wells A. Messersmith, Kyriakos P. Papadopoulos, Lia Gore, Muralidhar Beeram, Vanitha Ramakrishnan, (unknown), Joseph C. Beyer, L-Y Shih, Walter C. Darbonne, Xin Yan, Ron Yu, Hong Xiang, Rainer K. Brachmann, Colin D. Weekes	61
12	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer 2013 ·Cancer Chemotherapy and Pharmacology ·Amita Patnaik, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Muralidhar Beeram, Saı̈k Urien, Larry J. Schaaf, Sanaa Tahiri, Tanios Bekaii‐Saab, François Lokiec, Keyvan Rezaï, Aby Buchbinder	44
13	The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer 2012 ·Clinical Cancer Research ·Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Lon Smith, Shelly Gunn, Leslie Smetzer, Theresa A. Mays, Brianne Kaiser, Michael J. Wick, Cathy Alvarez, (unknown), G. Mangold, Amita Patnaik	352
14	A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer 2012 ·Cancer ·Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi	74
15	Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer 2010 ·Journal of Clinical Oncology ·Ian E. Krop, Muralidhar Beeram, Shanu Modi, Suzanne F. Jones, Scott N. Holden, Wei Yu, Sandhya Girish, Jay Tibbitts, Joo‐Hee Yi, Mark X. Sliwkowski, Fred Jacobson, Stuart Lutzker, Howard A. Burris	437
16	Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies 2009 ·Cancer Chemotherapy and Pharmacology ·Chia‐Chi Lin, Muralidhar Beeram, Eric K. Rowinsky, Chris H. Takimoto, Chee M. Ng, Charles E. Geyer, Louis Denis, Johann S. de Bono, Desirée Hao, Anthony W. Tolcher, Sun Young Rha, Jacques Jolivet, Amita Patnaik	2
17	Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors. 2007 ·Molecular Cancer Therapeutics ·Alexandria T. Phan, Chris H. Takimoto, (unknown), Leslie Wood, Henry Xiong, Kazuhiko Matsuno, (unknown), (unknown), Muralidhar Beeram	8
18	Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients (pts) with advanced malignancies 2006 ·Cancer Research ·Alejandro D. Ricart, Anthony W. Tolcher, Quincy S. Chu, Johann S. de Bono, Muralidhar Beeram, Desirée Hao, Monica Mita, Alain C. Mita, Geoffrey R. Weiss, Chris H. Takimoto, Eric K. Rowinsky	3
19	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma 2006 ·Cancer Chemotherapy and Pharmacology ·Monica Mita, Eric K. Rowinsky, Leonardo Forero, (unknown), Elżbieta Izbicka, Geoffrey R. Weiss, Muralidhar Beeram, Alain C. Mita, Johann S. de Bono, Anthony W. Tolcher, Lisa A. Hammond, Paul J. Simmons, (unknown), Chris H. Takimoto, Amita Patnaik	32
20	Targeting intracellular signal transduction 2002 ·Hematology/Oncology Clinics of North America ·Muralidhar Beeram, Amita Patnaik	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact